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The Affordable Medicines Facility - malaria (AMFm),
hosted by the Global Fund to Fight AIDS, Tuberculosis
and Malaria, is a financing mechanism which subsidizes
quality-assured Artemisinin-based Combination Therapies
(ACTs) for distribution to the public and private sectors,
complemented by supporting interventions to promote
rational drug use. AMFm has been in operation since
mid-2010 in eight national-scale operational pilots in
Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania
mainland, Uganda and Zanzibar. By March 2012, over 220
million co-paid ACT treatment doses had been ordered.
The Independent Evaluation (IE) of AMFm Phase 1 was
commissioned by the Global Fund to assess the impact of
AMFm on availability, price, market share and use of qual-
ity-assured ACTs in all the operational pilots as part of
evidence gathering needed to inform decisions regarding
the future of the AMFm. The assessment is based on a
pre- and post-test design with detailed documentation of
the implementation process and context, treating each
pilot independently. In each pilot, a nationally representa-
tive survey of outlets stocking antimalarial medicines was
conducted at the baseline (2009/10) and the endline
(2011).
In Ghana, the IE was carried out by a team comprising
collaborators from the Komfo Anokye Teaching Hospital,
Drugs for Neglected Diseases initiative, ICF International
and London School of Hygiene and Tropical Medicine. As
part of the IE, national level baseline and endline outlet
surveys were conducted in Ghana involving the collection
and analysis of primary data to answer three questions
related to the availability, affordability and market share of
quality-assured ACTs using a cluster sampling approach.
In-depth key informant interviews were also conducted to
provide the necessary context information to help in the
interpretation of the survey results.
In Ghana, 1,241 and 1,093 outlets were enumerated for
the baseline and endline outlet surveys respectively. For
the baseline survey, 57.3% (CI: 50.5-64) of outlets with any
antimalarials in stock at the time of the survey visit carried
artemisinin monotherapies, while only 30.7% (CI: 26.1-
35.8) of interviewed outlets had quality-assured ACTs in
stock at the time of the survey visit. At baseline, the med-
ian cost to patients of one adult equivalent treatment dose
of quality-assured ACTs was US$ 3.42 (IQR: 2.4-7.53) for
1,092 products. Detailed results on changes in quality-
assured ACT availability, price and market share over a
14-month period between baseline and endline surveys in
Ghana will be presented.
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